跳转至内容
Merck

P6402

Sigma-Aldrich

奋乃静

别名:

4-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-1-piperazineethanol

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H26ClN3OS
CAS号:
分子量:
403.97
EC號碼:
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

形狀

powder

品質等級

起源

Schering Plough

儲存溫度

2-8°C

SMILES 字串

ClC(C=C1)=CC2=C1SC3=CC=CC=C3N2CCCN4CCN(CCO)CC4

InChI

1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2

InChI 密鑰

RGCVKNLCSQQDEP-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

Perphenazine is an antipsychotic drug used in treating schizophrenia. It modulates antioxidant levels and helps in the management of oxidative injury in schizophrenia. However, it is less effective than the clozapine drug group in improving response to oxidative injury.

生化/生理作用

D2 dopamine receptor antagonist; α-adrenergic receptor antagonist and σ-receptor agonist; phenothiazine antipsychotic. Inhibits glutamate dehydrogenase in vitro.

特點和優勢

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Skin Sens. 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 1

1 of 1

J Nordenberg et al.
Biochemical pharmacology, 58(8), 1229-1236 (1999-09-16)
Some of the psychotropic agents widely used for the amelioration of anxiety, depression, and psychosis also show an effect at the cellular proliferation level. Surprisingly little research, however, has been directed to the antitumoral potential of these drugs, alone or
Donald E Addington et al.
The Journal of clinical psychiatry, 72(1), 75-80 (2010-09-28)
According to the American Psychiatric Association Clinical Practice Guidelines for schizophrenia, second-generation antipsychotics may be specifically indicated for the treatment of depression in schizophrenia. We examined the impact of these medications on symptoms of depression using the data from the
Angela M Koranek et al.
Schizophrenia research, 137(1-3), 137-140 (2012-03-01)
Results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicate that, with the exception of olanzapine, no substantial overall differences were identified between second generation antipsychotics (SGAs) and the first generation antipsychotic (FGA) perphenazine. This study evaluated the effect
Frank B Yoon et al.
Statistics in medicine, 30(16), 1917-1932 (2011-05-04)
In clinical trials multiple outcomes are often used to assess treatment interventions. This paper presents an evaluation of likelihood-based methods for jointly testing treatment effects in clinical trials with multiple continuous outcomes. Specifically, we compare the power of joint tests
Eric Hermes et al.
Journal of psychopharmacology (Oxford, England), 26(9), 1194-1200 (2012-04-21)
There is evidence to suggest that clozapine is underutilized in treatment-refractory schizophrenia. Data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), a multi-phase, randomized comparative effectiveness trial for schizophrenia, were used to identify factors associated with choosing randomization to

商品

This is an article about how proliferatively active cells require both a source of carbon and of nitrogen for the synthesis of macromolecules. Although a large proportion of tumor cells utilize aerobic glycolysis and shunt metabolites away from mitochondrial oxidative phosphorylation, many tumor cells exhibit increased mitochondrial activity.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门